Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kondo, Shunsuke ^a   Ueno, Hideki ^a   Hashimoto, Jun ^a   Morizane, Chigusa ^a   Koizumi, Fumiaki ^a   Okusaka, Takuji ^a   Tamura, Kenji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Angiogenesis factors; Circulating endothelial cells; Pancreatic carcinoma

Indexed keywords

ANGIOGENIC FACTOR; CHEMOKINE; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 8; VASCULOTROPIN;

AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CIRCULATING ENDOTHELIUM CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CARCINOMA; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; DEOXYCYTIDINE; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862611997     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-268     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003, 2:8. 10.1186/1476-4598-2-8, 149422, 12556241.
3. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88(10):2239-2245. 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V, 10820344.
4. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, Post S. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002, 25(2):122-129. 10.1097/00006676-200208000-00002, 12142733.
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027.
6. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011, 12(3):256-262. 10.1016/S1470-2045(11)70004-3, 21306953.
7. Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005, 93(2):228-235.
8. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006, 8(2):79-88. 10.1593/neo.05592, 1578513, 16611400.
9. Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, et al. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2009, 4(2):208-213. 10.1097/JTO.0b013e318193030d, 19179898.
10. Farace F, Massard C, Borghi E, Bidart JM, Soria JC. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 2007, 18(8):1421-1422. 10.1093/annonc/mdm367, 17693656.
11. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M, Pierga JY. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010, 21(4):729-733. 10.1093/annonc/mdp391, 19850639.
12. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010, 66(6):1051-1057. 10.1007/s00280-010-1257-5, 20130876.
13. Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia 2011, 13(10):980-990. 3201574, 22028623.
14. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97(11):3658-3661. 10.1182/blood.V97.11.3658, 11369666.
15. Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G, Martinelli G, Bertolini F. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003, 522:83-97. 10.1007/978-1-4615-0169-5_9, 12674213.
16. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011, 30(1):83-95. 10.1007/s10555-011-9281-4, 21249423.
17. Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, Tong Z, Guha S. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer 2009, 124(4):853-861. 10.1002/ijc.24040, 2684108, 19035451.
18. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28(22):3617-3622. 10.1200/JCO.2010.28.1386, 2917317, 20606091.
19. Bertolini F, Marighetti P, Shaked Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim Biophys Acta 2010, 1806(2):131-137.
20. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996, 2(11):1843-1849.
21. Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R, Van Damme M. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 2002, 21(2):417-425.
22. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14(1):13-19. 10.1097/00001813-200301000-00003, 12544254.
23. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005, 11(9):3514-3522. 10.1158/1078-0432.CCR-04-2271, 15867254.
24. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 2007, 13(15 Pt 2):s4617-s4622.